Indoco Remedies Reports Negative Financial Performance in Q1 2024

Indoco Remedies, a smallcap pharmaceutical company, recently announced its financial results for the quarter ended March 2024. According to the latest report, the company has seen a very negative performance in terms of financials, with a score of -21, which has improved from -23 in the last three months. The profit before tax (PBT) less other income for the quarter was at Rs 10.59 crore, which is a significant decrease of 70.2% compared to the average PBT of the previous four quarters, which was Rs 35.57 crore. This indicates a very negative trend in the near term for PBT. Similarly, the profit after tax (PAT) for the quarter was at Rs 9.52 crore, a decrease of 64.5% compared to the average PAT of the previous four quarters, which was Rs 26.80 crore. This also shows a very negative trend in the near term for PAT. The company's operating profit to interest ratio for the quarter was at its lowest in the last five quarters, at 4.06 times. This indicates a deteriorating ability to manage interest payments. The interest cost for the quarter was also at its highest in the last five quarters, at Rs 12.05 crore, which has increased by 19.66% compared to the previous quarter. This signifies an increase in borrowings for the company. The operating profit (PBDIT) for the quarter was also at its lowest in the last five quarters, at Rs 48.87 crore. This shows a negative trend in the near term for operating profit. The operating profit margin for the quarter was also at its lowest in the last five quarters, at 10.87%. This indicates a deterioration in the company's efficiency. Overall, the financial performance of Indoco Remedies for the quarter ended March 2024 has been very negative. The company's ability to manage interest payments and its efficiency have deteriorated, and there is a negative trend in the near term for PBT and PAT. Based on these factors, MarketsMOJO has given a 'Sell' call for the company's stock.